depression

(MENAFN - ACCESSWIRE) AUSTIN, TX / ACCESS Newswire / April 2, 2026 / Unfortunately, chronic back pain has silenced too many lives for too long. It has stolen sleep, canceled plans, ended careers, ...

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met In a post hoc analysis of participants (n=54)...

WALTHAM, Mass.--(BUSINESS WIRE)---- $CYCN--Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that they have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Korsana Biosciences, Inc. and

$11.6M Department of Defense-supported multi-side study evaluates rapid, personalized, drug-free neuromodulation therapy at leading research centers